Pay vs Performance Disclosure - USD ($)

12 Months Ended

Dec. 31, 2024

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Pay vs Performance Disclosure

Pay vs Performance Disclosure, Table

									Value of Initial Fixed $100
									Investment Based On:
											Peer Group
					Average						Total
					Summary		Average				Stockholder
	Summary				Compensation		Compensation				Return
	Compensation		Compensation		Table Total		Actually Paid		Total		(Nasdaq
	Table Total		Actually Paid		for Non-PEO		to Non-PEO		Stockholder		Biotechnology		Net Income		Total Revenue
Year	for PEO(1)		to PEO(2)		NEOs(3)		NEOs(4)		Return(5)		Index)(6)		(in thousands)(7)		(in thousands)(8)
2024	$	13,032,674	$	95,390,804	$	6,124,794	$	46,461,399	$	469.87	$	118.20	$	(190,426)	$	1,696,911
2023	$	12,727,887	$	32,772,214	$	4,882,630	$	12,994,682	$	185.93	$	118.87	$	(434,801)	$	1,082,571
2022	$	8,246,281	$	(10,478,887)	$	4,548,786	$	(4,682,784)	$	119.23	$	113.65	$	(547,799)	$	820,222
2021	$	23,343,147	$	17,842,930	$	8,415,636	$	7,334,133	$	277.20	$	126.45	$	(471,716)	$	625,486
2020	$	8,083,213	$	60,865,789	$	2,795,161	$	24,672,935	$	295.40	$	126.42	$	(229,743)	$	391,005

(1) Our PEO for each year reported is Steven Chapman, our Chief Executive Officer. The dollar amounts reported in this column are the amounts of total compensation reported for Mr. Chapman in the “Total” column of the Summary Compensation Table in the applicable fiscal year.

(2) In accordance with SEC rules, the following adjustments were made to determine the compensation actually paid to our PEO during fiscal years 2024, 2023, 2022, 2021, and 2020, which consisted solely of adjustments to the PEO’s equity awards:

Description of Adjustment	2024		2023		2022		2021		2020
Summary Compensation Table – Total Compensation	$	13,032,674	$	12,727,887	$	8,246,281	$	23,343,147	$	8,083,213
- grant date fair value of option awards and stock awards granted in the covered fiscal year	$	(11,284,474)	$	(11,133,142)	$	(7,093,675)	$	(22,417,562)	$	(7,291,047)
+ fair value at fiscal year end of outstanding and unvested option awards and stock awards granted in the covered fiscal year	$	40,945,878	$	23,915,639	$	4,352,420	$	14,282,938	$	25,400,473
+ change in fair value of outstanding and unvested option awards and stock awards granted in prior fiscal years	$	44,724,070	$	6,009,186	$	(11,074,522)	$	(745,043)	$	21,714,867
+ fair value on vesting date of option awards and stock awards granted in the covered fiscal year that vested during the covered fiscal year	$	833,838	$	533,851	$	550,650	$	0	$	6,497,053
+ change in fair value as of the vesting date of option awards and stock awards granted in prior fiscal years that vested in the covered fiscal year	$	7,138,818	$	718,793	$	(5,460,040)	$	3,379,450	$	6,461,230
- fair value of as of prior fiscal year end of option awards and stock awards granted in prior fiscal years that failed to meet applicable vesting conditions during the covered fiscal year	$	0	$	0	$	0	$	0	$	0
+ dollar value of dividends or earnings paid on option awards or stock awards in the covered fiscal year prior to vesting that are not otherwise included in total compensation	$	0	$	0	$	0	$	0	$
Total Equity Adjustments (subtotal)*	$	0	$	0	$	(18,725,167)	$	(5,500,217)	$	52,782,576
Compensation Actually Paid	$	95,390,804	$	32,772,214	$	(10,478,887)	$	17,842,930	$	60,865,789

* Calculations reflect equity granted over a span of eight years of service prior to, as well as during, the reported fiscal years.

(3) The non-PEO NEOs for each year reported are as follows:

For 2024: Michael Brophy, John Fesko, Solomon Moshkevich, and Matthew Rabinowitz

For 2023: Michael Brophy, Robert Schueren, Daniel Rabinowitz, and Matthew Rabinowitz

For 2022: Michael Brophy, Robert Schueren, Daniel Rabinowitz, and Matthew Rabinowitz

For 2021: Michael Brophy, Robert Schueren, Daniel Rabinowitz, and Matthew Rabinowitz

For 2020: Michael Brophy, Robert Schueren, Matthew Rabinowitz, and Jonathan Sheena

The dollar amounts reported in this column represent the average of the amounts reported for the non-PEO NEOs in the “Total” column of the Summary Compensation Table in the applicable fiscal year.

(4) In accordance with SEC rules, the following adjustments were made to determine the compensation actually paid on average to our non-PEO NEOs during fiscal years 2024, 2023, 2023, 2021, and 2020, which consisted solely of adjustments to the non-PEO NEOs’ equity awards:

Description of Adjustment	2024		2023		2022		2021		2020
Summary Compensation Table – Total Compensation	$	6,124,794	$	4,882,630	$	4,548,786	$	8,415,636	$	2,795,161
- grant date fair value of option awards and stock awards granted in the covered fiscal year	$	(5,334,407)	$	(4,249,439)	$	(3,982,802)	$	(7,808,661)	$	(2,262,392)
+ fair value at fiscal year end of outstanding and unvested option awards and stock awards granted in the covered fiscal year	$	19,355,974	$	9,484,948	$	2,256,160	$	6,278,945	$	10,304,088
+ change in fair value of outstanding and unvested option awards and stock awards granted in prior fiscal years	$	23,293,949	$	2,199,442	$	(4,777,779)	$	(488,996)	$	8,640,852
+ fair value on vesting date of option awards and stock awards granted in the covered fiscal year that vested during the covered fiscal year	$	383,798	$	175,978	$	256,134	$	0	$	562,800
+ change in fair value as of the vesting date of option awards and stock awards granted in prior fiscal years that vested in the covered fiscal year	$	2,637,291	$	501,123	$	(2,983,283)	$	937,209	$	4,632,426
- fair value of as of prior fiscal year end of option awards and stock awards granted in prior fiscal years that failed to meet applicable vesting conditions during the covered fiscal year	$	0	$	0	$	0	$	0	$	0
+ dollar value of dividends or earnings paid on option awards or stock awards in the covered fiscal year prior to vesting that are not otherwise included in total compensation	$	0	$	0	$	0	$	0	$	0
Total Equity Adjustments (subtotal)*	$	0	$	0	$	(9,231,569)	$	(1,081,503)	$	21,877,775
Compensation Actually Paid	$	46,461,399	$	12,994,682	$	(4,682,784)	$	7,334,133	$	24,672,935

* Calculations reflect equity granted over a span of up to eight years of service prior to, as well as during, the reported fiscal years (2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024).

(5) Cumulative total stockholder return on our shares of common stock from December 31, 2019 through December 31, 2020, December 31, 2021, December 31, 2022, December 31, 2023, and December 31, 2024, respectively. Assumes the investment of $100 on December 31, 2019 in our shares of common stock and assumes the reinvestment of dividends, if any, although dividends have never been declared on our shares of common stock.

(6) Cumulative total stockholder return on the NASDAQ Biotechnology Index from December 31, 2019 through December 31, 2020, December 31, 2021, December 31, 2022, December 31, 2023, and December 31, 2024, respectively. Assumes the investment of $100 on December 31, 2019 in the NASDAQ Biotechnology Index and assumes the reinvestment of dividends.

(7) The dollar amounts reported represent the amount of net income reflected in our audited financial statements for the applicable year.

(8) The dollar amounts reported represent the amount of total revenue reflected in our audited financial statements for the applicable year.

Company Selected Measure Name

Total Revenue

Named Executive Officers, Footnote

(1) Our PEO for each year reported is Steven Chapman, our Chief Executive Officer. The dollar amounts reported in this column are the amounts of total compensation reported for Mr. Chapman in the “Total” column of the Summary Compensation Table in the applicable fiscal year.

(3) The non-PEO NEOs for each year reported are as follows:

For 2024: Michael Brophy, John Fesko, Solomon Moshkevich, and Matthew Rabinowitz

For 2023: Michael Brophy, Robert Schueren, Daniel Rabinowitz, and Matthew Rabinowitz

For 2022: Michael Brophy, Robert Schueren, Daniel Rabinowitz, and Matthew Rabinowitz

For 2021: Michael Brophy, Robert Schueren, Daniel Rabinowitz, and Matthew Rabinowitz

For 2020: Michael Brophy, Robert Schueren, Matthew Rabinowitz, and Jonathan Sheena

The dollar amounts reported in this column represent the average of the amounts reported for the non-PEO NEOs in the “Total” column of the Summary Compensation Table in the applicable fiscal year.

Peer Group Issuers, Footnote

(6) Cumulative total stockholder return on the NASDAQ Biotechnology Index from December 31, 2019 through December 31, 2020, December 31, 2021, December 31, 2022, December 31, 2023, and December 31, 2024, respectively. Assumes the investment of $100 on December 31, 2019 in the NASDAQ Biotechnology Index and assumes the reinvestment of dividends.

PEO Total Compensation Amount

$ 13,032,674

$ 12,727,887

$ 8,246,281

$ 23,343,147

$ 8,083,213

PEO Actually Paid Compensation Amount

$ 95,390,804

32,772,214

(10,478,887)

17,842,930

60,865,789

Adjustment To PEO Compensation, Footnote

(2) In accordance with SEC rules, the following adjustments were made to determine the compensation actually paid to our PEO during fiscal years 2024, 2023, 2022, 2021, and 2020, which consisted solely of adjustments to the PEO’s equity awards:

Description of Adjustment	2024		2023		2022		2021		2020
Summary Compensation Table – Total Compensation	$	13,032,674	$	12,727,887	$	8,246,281	$	23,343,147	$	8,083,213
- grant date fair value of option awards and stock awards granted in the covered fiscal year	$	(11,284,474)	$	(11,133,142)	$	(7,093,675)	$	(22,417,562)	$	(7,291,047)
+ fair value at fiscal year end of outstanding and unvested option awards and stock awards granted in the covered fiscal year	$	40,945,878	$	23,915,639	$	4,352,420	$	14,282,938	$	25,400,473
+ change in fair value of outstanding and unvested option awards and stock awards granted in prior fiscal years	$	44,724,070	$	6,009,186	$	(11,074,522)	$	(745,043)	$	21,714,867
+ fair value on vesting date of option awards and stock awards granted in the covered fiscal year that vested during the covered fiscal year	$	833,838	$	533,851	$	550,650	$	0	$	6,497,053
+ change in fair value as of the vesting date of option awards and stock awards granted in prior fiscal years that vested in the covered fiscal year	$	7,138,818	$	718,793	$	(5,460,040)	$	3,379,450	$	6,461,230
- fair value of as of prior fiscal year end of option awards and stock awards granted in prior fiscal years that failed to meet applicable vesting conditions during the covered fiscal year	$	0	$	0	$	0	$	0	$	0
+ dollar value of dividends or earnings paid on option awards or stock awards in the covered fiscal year prior to vesting that are not otherwise included in total compensation	$	0	$	0	$	0	$	0	$
Total Equity Adjustments (subtotal)*	$	0	$	0	$	(18,725,167)	$	(5,500,217)	$	52,782,576
Compensation Actually Paid	$	95,390,804	$	32,772,214	$	(10,478,887)	$	17,842,930	$	60,865,789

* Calculations reflect equity granted over a span of eight years of service prior to, as well as during, the reported fiscal years.

Non-PEO NEO Average Total Compensation Amount

$ 6,124,794

4,882,630

4,548,786

8,415,636

2,795,161

Non-PEO NEO Average Compensation Actually Paid Amount

$ 46,461,399

12,994,682

(4,682,784)

7,334,133

24,672,935

Adjustment to Non-PEO NEO Compensation Footnote

(4) In accordance with SEC rules, the following adjustments were made to determine the compensation actually paid on average to our non-PEO NEOs during fiscal years 2024, 2023, 2023, 2021, and 2020, which consisted solely of adjustments to the non-PEO NEOs’ equity awards:

Description of Adjustment	2024		2023		2022		2021		2020
Summary Compensation Table – Total Compensation	$	6,124,794	$	4,882,630	$	4,548,786	$	8,415,636	$	2,795,161
- grant date fair value of option awards and stock awards granted in the covered fiscal year	$	(5,334,407)	$	(4,249,439)	$	(3,982,802)	$	(7,808,661)	$	(2,262,392)
+ fair value at fiscal year end of outstanding and unvested option awards and stock awards granted in the covered fiscal year	$	19,355,974	$	9,484,948	$	2,256,160	$	6,278,945	$	10,304,088
+ change in fair value of outstanding and unvested option awards and stock awards granted in prior fiscal years	$	23,293,949	$	2,199,442	$	(4,777,779)	$	(488,996)	$	8,640,852
+ fair value on vesting date of option awards and stock awards granted in the covered fiscal year that vested during the covered fiscal year	$	383,798	$	175,978	$	256,134	$	0	$	562,800
+ change in fair value as of the vesting date of option awards and stock awards granted in prior fiscal years that vested in the covered fiscal year	$	2,637,291	$	501,123	$	(2,983,283)	$	937,209	$	4,632,426
- fair value of as of prior fiscal year end of option awards and stock awards granted in prior fiscal years that failed to meet applicable vesting conditions during the covered fiscal year	$	0	$	0	$	0	$	0	$	0
+ dollar value of dividends or earnings paid on option awards or stock awards in the covered fiscal year prior to vesting that are not otherwise included in total compensation	$	0	$	0	$	0	$	0	$	0
Total Equity Adjustments (subtotal)*	$	0	$	0	$	(9,231,569)	$	(1,081,503)	$	21,877,775
Compensation Actually Paid	$	46,461,399	$	12,994,682	$	(4,682,784)	$	7,334,133	$	24,672,935

* Calculations reflect equity granted over a span of up to eight years of service prior to, as well as during, the reported fiscal years (2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024).

Compensation Actually Paid vs. Total Shareholder Return

Compensation Actually Paid vs. Net Income

Compensation Actually Paid vs. Company Selected Measure

Total Shareholder Return Vs Peer Group

Tabular List, Table

Most Important Performance Measures

For 2024, the most important performance measures used to inform our executive compensation decisions included the following:

● Total revenue

● Product gross margin

● Operating cash flow  

Total Shareholder Return Amount

$ 469.87

185.93

119.23

277.20

295.40

Peer Group Total Shareholder Return Amount

118.20

118.87

113.65

126.45

126.42

Net Income (Loss)

$ (190,426,000)

$ (434,801,000)

$ (547,799,000)

$ (471,716,000)

$ (229,743,000)

Company Selected Measure Amount

1,696,911,000

1,082,571,000

820,222,000

625,486,000

391,005,000

PEO Name

Steven Chapman

Measure:: 1

Pay vs Performance Disclosure

Name

Total revenue

Non-GAAP Measure Description

(8) The dollar amounts reported represent the amount of total revenue reflected in our audited financial statements for the applicable year.

Measure:: 2

Pay vs Performance Disclosure

Name

Product gross margin

Measure:: 3

Pay vs Performance Disclosure

Name

Operating cash flow

PEO | Total Equity Adjustments (subtotal)

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

$ 0

$ 0

$ (18,725,167)

$ (5,500,217)

$ 52,782,576

PEO | grant date fair value of option awards and stock awards granted in the covered fiscal year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(11,284,474)

(11,133,142)

(7,093,675)

(22,417,562)

(7,291,047)

PEO | fair value at fiscal year end of outstanding and unvested option awards and stock awards granted in the covered fiscal year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

40,945,878

23,915,639

4,352,420

14,282,938

25,400,473

PEO | change in fair value of outstanding and unvested option awards and stock awards granted in prior fiscal years

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

44,724,070

6,009,186

(11,074,522)

(745,043)

21,714,867

PEO | fair value on vesting date of option awards and stock awards granted in the covered fiscal year that vested during the covered fiscal year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

833,838

533,851

550,650

0

6,497,053

PEO | change in fair value as of the vesting date of option awards and stock awards granted in prior fiscal years that vested in the covered fiscal year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

7,138,818

718,793

(5,460,040)

3,379,450

6,461,230

PEO | fair value of as of prior fiscal year end of option awards and stock awards granted in prior fiscal years that failed to meet applicable vesting conditions during the covered fiscal year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

0

0

0

0

0

PEO | dollar value of dividends or earnings paid on option awards or stock awards in the covered fiscal year prior to vesting that are not otherwise included in total compensation

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

0

0

0

0

Non-PEO NEO | Total Equity Adjustments (subtotal)

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

0

0

(9,231,569)

(1,081,503)

21,877,775

Non-PEO NEO | grant date fair value of option awards and stock awards granted in the covered fiscal year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(5,334,407)

(4,249,439)

(3,982,802)

(7,808,661)

(2,262,392)

Non-PEO NEO | fair value at fiscal year end of outstanding and unvested option awards and stock awards granted in the covered fiscal year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

19,355,974

9,484,948

2,256,160

6,278,945

10,304,088

Non-PEO NEO | change in fair value of outstanding and unvested option awards and stock awards granted in prior fiscal years

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

23,293,949

2,199,442

(4,777,779)

(488,996)

8,640,852

Non-PEO NEO | fair value on vesting date of option awards and stock awards granted in the covered fiscal year that vested during the covered fiscal year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

383,798

175,978

256,134

0

562,800

Non-PEO NEO | change in fair value as of the vesting date of option awards and stock awards granted in prior fiscal years that vested in the covered fiscal year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

2,637,291

501,123

(2,983,283)

937,209

4,632,426

Non-PEO NEO | fair value of as of prior fiscal year end of option awards and stock awards granted in prior fiscal years that failed to meet applicable vesting conditions during the covered fiscal year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

0

0

0

0

0

Non-PEO NEO | dollar value of dividends or earnings paid on option awards or stock awards in the covered fiscal year prior to vesting that are not otherwise included in total compensation

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

$ 0

$ 0

$ 0

$ 0

$ 0